Therapeutic potential of targeting galectins-A biomaterials-focused perspective

Among all the biological entities involved in the immune response, galectins, a family of glycan-binding proteins, have been described as key in immune cell homeostasis and modulation. More importantly, only some galectin family members are crucial in the resolution of inflammation, while others perpetuate the immune response in a pathological context. As they are expressed in most major diseases, their potential as targets for new therapies seems promising. Most of the galectin family members' ubiquitous expression points to the need for targeted treatments to ensure effectiveness. Engineered biomaterials are emerging as a promising method to improve galectin-targeted strategies' therapeutic performance. In this review, we provide an overview of the role of galectins in health and disease and their potential as therapeutic targets, as well as the state-of-the-art and future directions of galectin-targeted biomaterials.

Automated summary

Galectins, a family of glycan-binding proteins, play a key role in immune cell homeostasis and modulation. Some members of the galectin family are crucial in the resolution of inflammation, while others perpetuate the immune response in a pathological context. They have the potential to be targeted for new therapies, and engineered biomaterials show promise in improving the therapeutic performance of galectin-targeted strategies.